{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:45:12Z","timestamp":1747169112684,"version":"3.40.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.pharma.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T17:18:22Z","timestamp":1707412702000},"page":"654-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-9513","authenticated-orcid":false,"given":"Fairouz","family":"Haouatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikram K.","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlem","family":"Goumidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Yafour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houari","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2002","article-title":"Plasma cell neoplasms (including multiple myeloma) treatment (PDQ\u00ae): health professional version","series-title":"PDQ Cancer Information Summaries [Internet]","key":"10.1016\/j.pharma.2024.02.001_bib0195"},{"key":"10.1016\/j.pharma.2024.02.001_bib0200","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"unstructured":"Globocan. Algeria [Internet]. World Health organization. 2021. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/12-algeria-fact-sheets.pdf.","key":"10.1016\/j.pharma.2024.02.001_bib0205"},{"issue":"5","key":"10.1016\/j.pharma.2024.02.001_bib0210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2024.02.001_bib0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.hemonc.2017.05.019","article-title":"Hematopoietic stem cell transplantation in Algeria","volume":"10","author":"Bekadja","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.pharma.2024.02.001_bib0220","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/curroncol29040223","article-title":"The economic burden of cancer in Canada from a societal perspective","volume":"29","author":"Garaszczuk","year":"2022","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.pharma.2024.02.001_bib0225","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.pharma.2024.02.001_bib0230","first-page":"181","article-title":"Impact de l\u2019\u00e2ge et de la transition d\u00e9mographique sur les h\u00e9mopathies malignes en Alg\u00e9rie. \u00c9tude de m\u00e9ta analyse portant sur une p\u00e9riode allant de 1992 \u00e0 2021 (30 ans)","volume":"4","author":"Bekadja","year":"2020","journal-title":"AJHS"},{"issue":"5","key":"10.1016\/j.pharma.2024.02.001_bib0235","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pharma.2024.02.001_bib0240","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","article-title":"Beyond medicines barriers: exploring the true cost of multiple myeloma","volume":"25","author":"Choon-Quinones","year":"2022","journal-title":"J Med Econ"},{"issue":"11","key":"10.1016\/j.pharma.2024.02.001_bib0245","first-page":"762","article-title":"Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria. 10 years\u2019 experience","volume":"100","author":"Bekadja","year":"2022","journal-title":"Tunis Med"},{"issue":"1","key":"10.1016\/j.pharma.2024.02.001_bib0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/13696998.2022.2144056","article-title":"Systematic literature review of health economic models developed for multiple myeloma to support future analyses","volume":"26","author":"Choon-Quinones","year":"2023","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.pharma.2024.02.001_bib0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.retram.2019.11.003","article-title":"Epidemiological and immunochemical parameters of monoclonal plasma cell dyscrasias of 2121 cases in Algeria","volume":"68","author":"Belouni","year":"2020","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.pharma.2024.02.001_bib0260","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.pharma.2024.02.001_bib0265","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5639\/gabij.2016.0504.042","article-title":"Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia","volume":"5","author":"Garg","year":"2016","journal-title":"GaBI J"},{"issue":"24","key":"10.1016\/j.pharma.2024.02.001_bib0270","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.pharma.2024.02.001_bib0275","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s44228-023-00036-8","article-title":"Current advances in multiple myeloma: a post International Myeloma Society (IMS 2022) round table debate by the International Academy for Clinical Hematology (IACH)","volume":"5","author":"Bahlis","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"3","key":"10.1016\/j.pharma.2024.02.001_bib0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2024.02.001_bib0285","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.pharma.2024.02.001_bib0290","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.hemonc.2020.06.002","article-title":"Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma","volume":"14","author":"Lad","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.pharma.2024.02.001_bib0295","doi-asserted-by":"crossref","first-page":"e927084","DOI":"10.12659\/AOT.927084","article-title":"Outcomes of non-cryopreserved versus cryopreserved peripheral blood stem cells for autologous stem cell transplantation in multiple myeloma","volume":"25","author":"Piriyakhuntorn","year":"2020","journal-title":"Ann Transplant"},{"issue":"2","key":"10.1016\/j.pharma.2024.02.001_bib0300","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2013.09.001","article-title":"High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells","volume":"14","author":"Kayal","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.pharma.2024.02.001_bib0305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0012.2011.01432.x","article-title":"Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience","volume":"26","author":"Ramzi","year":"2012","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.pharma.2024.02.001_bib0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000074221","article-title":"Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience","volume":"110","author":"Ruiz-Arguelles","year":"2003","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.pharma.2024.02.001_bib0315","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.V112.11.2373.2373","article-title":"Payer costs of autologous stem cell transplant: results from a U.S. claims data analysis","volume":"112","author":"Pelletier","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.pharma.2024.02.001_bib0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12288-017-0843-7","article-title":"Cost of treatment of multiple myeloma in a public sector tertiary care hospital of North India","volume":"34","author":"Kaur","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"10.1016\/j.pharma.2024.02.001_bib0325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/theoncologist.2014-0218","article-title":"Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico","volume":"20","author":"Jaime-P\u00e9rez","year":"2015","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.pharma.2024.02.001_bib0330","first-page":"1266","article-title":"Myeloid growth factors clinical practice guidelines in oncology","volume":"11","author":"Crawford","year":"2013","journal-title":"JNCCN"},{"issue":"Supplement 5","key":"10.1016\/j.pharma.2024.02.001_bib0335","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pharma.2024.02.001_bib0340","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/1078155218792698","article-title":"Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia","volume":"25","author":"Zullo","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.pharma.2024.02.001_bib0345","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jcyt.2015.05.010","article-title":"Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients","volume":"17","author":"Martino","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharma.2024.02.001_bib0350","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1186\/s12913-015-1205-5","article-title":"Excess length of stay and economic consequences of adverse events in Dutch hospital patients","volume":"15","author":"Hoogervorst-Schilp","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"10.1016\/j.pharma.2024.02.001_bib0355","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/bmt.2017.113","article-title":"Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation","volume":"52","author":"Pavl\u016f","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.pharma.2024.02.001_bib0360","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41409-018-0210-9","article-title":"Trends and outcomes-first 100 bone marrow transplants at a tertiary care center in Islamabad, Pakistan","volume":"53","author":"Mushtaq","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.pharma.2024.02.001_bib0365","doi-asserted-by":"crossref","first-page":"100695","DOI":"10.1016\/j.hlpt.2022.100695","article-title":"High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records","volume":"11","author":"Bennink","year":"2022","journal-title":"Health Policy Technol"},{"key":"10.1016\/j.pharma.2024.02.001_bib0370","doi-asserted-by":"crossref","first-page":"100243","DOI":"10.1016\/j.jbo.2019.100243","article-title":"Unplanned admissions for patients with myeloma in the UK: low frequency but high costs","volume":"17","author":"Kolovos","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.pharma.2024.02.001_bib0375","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vhri.2023.01.001","article-title":"An economic model to establish the costs associated with routes to presentation for patients with multiple myeloma in the United Kingdom","volume":"35","author":"Porteous","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"Suppl. 1","key":"10.1016\/j.pharma.2024.02.001_bib0380","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1182\/blood-2022-163772","article-title":"Is VTD the best first line therapy for multiple myeloma in an environment with limited resources? An analysis of outcomes and costs","volume":"140","author":"Gomez","year":"2022","journal-title":"Blood"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:53:10Z","timestamp":1718135590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003450924000063"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.02.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}